Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dyslipidemia of central obesity and insulin resistance.

Literature DB >> 10189557

Dyslipidemia of central obesity and insulin resistance.

J D Brunzell¹, J E Hokanson.

Abstract

Entities: Disease Gene

Mesh：

Year: 1999 PMID： 10189557

Source DB: PubMed Journal: Diabetes Care ISSN： 0149-5992 Impact factor: 19.112

Keyword Cloud
Cited

× No keyword cloud information.

27 in total

Review 1. The emerging role of HDL in glucose metabolism.

Authors: Brian G Drew; Kerry-Anne Rye; Stephen J Duffy; Philip Barter; Bronwyn A Kingwell
Journal: Nat Rev Endocrinol Date: 2012-01-24 Impact factor: 43.330

2. Reduced cardiovascular risk after bariatric surgery is linked to plasma ceramides, apolipoprotein-B100, and ApoB100/A1 ratio.

Authors: Helen M Heneghan; Hazel Huang; Sangeeta R Kashyap; Heather L Gornik; Arthur J McCullough; Philip R Schauer; Stacy A Brethauer; John P Kirwan; Takhar Kasumov
Journal: Surg Obes Relat Dis Date: 2011-12-20 Impact factor: 4.734

Review 3. Evolving pathophysiologic concepts in nonalcoholic steatohepatitis.

Authors: Brent A Neuschwander-Tetri
Journal: Curr Gastroenterol Rep Date: 2002-02

4. Impact of mifepristone, a glucocorticoid/progesterone antagonist, on HDL cholesterol, HDL particle concentration, and HDL function.

Authors: Stephanie T Page; Ronald M Krauss; Coleman Gross; Brian Ishida; Jay W Heinecke; Chongren Tang; John K Amory; Peter M Schaefer; Cheryl J Cox; John Kane; Jonathan Q Purnell; Richard L Weinstein; Tomáš Vaisar
Journal: J Clin Endocrinol Metab Date: 2012-03-07 Impact factor: 5.958

9. Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial.

Authors: Jonathan Q Purnell; Raj K Dev; Michael W Steffes; Patricia A Cleary; Jerry P Palmer; Irl B Hirsch; John E Hokanson; John D Brunzell
Journal: Diabetes Date: 2003-10 Impact factor: 9.461

10. Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat diet-induced obese mice.

Authors: Sunhyo Jeong; Michung Yoon
Journal: Exp Mol Med Date: 2009-06-30 Impact factor: 8.718

Dyslipidemia of central obesity and insulin resistance.

Review 1. The emerging role of HDL in glucose metabolism.

2. Reduced cardiovascular risk after bariatric surgery is linked to plasma ceramides, apolipoprotein-B100, and ApoB100/A1 ratio.

Review 3. Evolving pathophysiologic concepts in nonalcoholic steatohepatitis.

4. Impact of mifepristone, a glucocorticoid/progesterone antagonist, on HDL cholesterol, HDL particle concentration, and HDL function.

Review 5. Dyslipidemia in diabetes mellitus and cardiovascular disease.

Review 6. Role for combination therapy in diabetic dyslipidemia.

7. Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women.

8. Early effects of gastric bypass on endothelial function, inflammation, and cardiovascular risk in obese patients.

9. Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial.

10. Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat diet-induced obese mice.